Your session is about to expire
← Back to Search
Low-Dose Naltrexone for Post-COVID Fatigue Syndrome
Study Summary
This trial will study whether low-dose naltrexone can help with symptoms of Post-COVID-19 Fatigue Syndrome. LDN is a medication that is given in doses of 1-4.5 mg and is safe and well-tolerated. It may help to reduce pain and inflammation and improve well-being and immune function.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 43 Patients • NCT04409041Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had COVID-19 more than 3 months ago, confirmed by a test or doctor.I had ME/CFS or fibromyalgia before getting COVID-19.I have not taken any opioid medications in the last 15 days.I do not have acute hepatitis, liver failure, or severe kidney failure.I will be using opioid medications during the trial.I am between 19 and 69 years old.I have used naltrexone in the last 30 days.I agree to keep my current medications unchanged during the trial, unless my doctor advises otherwise.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Low-Dose Naltrexone
- Group 2: Placebo
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
Frequently Asked Questions
Does this clinical experiment accept participants under the age of 30?
"As specified in the trial's eligibility guidelines, 19 is the lowest age of admission while 69 marks the upper limit."
Are there any existing opportunities to become involved in this research endeavor?
"Clinicaltrials.gov reports that this research is not presently enrolling patients; the trial was first posted on March 1st 2023 and last updated December 6th 2022. Nevertheless, 1617 other clinical trials are actively seeking participants as of now."
Can I be included in this exploration?
"This medical trial requires 160 participants, aged between 19 and 69 years old who have the specified syndrome. For eligibility in this study, individuals must accept contraception for its duration if female, maintain regular medications dose unless essential changes are prescribed by a doctor, verify SARS-CoV-2 case status within 3 to 6 months of recruitment through testing or clinical confirmation from a physician, and meet all relevant diagnostic criteria as authenticated by PCRC."
Is Low-Dose Naltrexone sanctioned by the FDA?
"Despite the lack of efficacy data, Low-Dose Naltrexone is thought to be relatively safe and thus was assigned a rating of 2."
Who else is applying?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger